ArticleCardiovascular therapeutics2026
Epigenetic Regulation of ITGB7 Promotes Coronary Heart Disease via Immune and Metabolic Pathways: A Multimodal Mendelian Randomization Study.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic Regulation of ITGB7 Promotes Coronary Heart Disease via Immune and Metabolic Pathways: A Multimodal Mendelian Randomization Study.Cardiovascular therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary heart disease (CHD) is a leading cause of cardiovascular mortality worldwide, with its pathogenesis being complex and not yet fully understood. The rapid development of genomics, especially in epigenetic research, has provided essential tools for identifying new pathogenic targets. This study is aimed at systematically exploring the molecular mechanisms of CHD using protein quantitative trait locus (pQTL) data and multiomics Mendelian randomization (MR) approaches, with a specific focus on the epigenetic regulation of the key gene ITGB7. Methods: The study first integrated 1812 Results: MR analysis identified 17 genes significantly positively associated with CHD, with PCSK9 and ITGB7 showing significant upregulation in the peripheral blood of CHD patients. Mediation analysis revealed that the DNA methylation site cg14524975 (beta_ Conclusion: This study identifies ITGB7 as a novel pathogenic gene for CHD and reveals its multiomics mechanisms in promoting CHD development through DNA methylation regulation, immune response activation, and metabolic pathway disruption. The findings provide valuable theoretical insights and potential biomarkers for the pathogenesis and targeted intervention of CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.